Search results
Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?
Investor's Business Daily· 15 hours agoNeurocrine and partner Takeda Pharmaceutical tested their drug in adults with major depressive ...
Mid-Stage Win for Novel Depression Agent; 'Floordrobe' Disorder; CIA Mind Control
MedPage Today· 24 hours agoIn the phase II SAVITRI study, once-daily treatment with an investigational, AMPA positive allosteric modulator (NBI-1065845) significantly reduced depression scores by day 28 in people with ...
Neurocrine scores surprise win with depression drug
BioPharma Dive via Yahoo Finance· 2 days agoShares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major ...
Is Europe Taking Too Long to Adopt TMS for Major Depression?
Medscape· 6 days agoRepetitive transcranial magnetic stimulation (rTMS) can be useful treatment for some people with ...
Antidepressants Differ by Long-Term Response in Major Depression
Psychiatric Times· 2 days agoAntidepressants differ in improving symptoms and preventing relapse of major depressive disorder...
Troubled former Yakima officer coached and taught in Richland schools before killings
The Columbian· 14 hours agoThe former Yakima police officer accused of killing his ex-wife at William Wiley Elementary School...
Many mental-health conditions have bodily triggers
The Economist· 11 hours agoTHE TICS started when Jessica Huitson was only 12 years old. In fact, Jessica had an autoimmune condition brought on by a bacterial infection with Streptococcus. Ms Huitson is not alone in having ...
Early Evidence Supports Ketogenic Diet for Mental Illness
Medscape· 7 days agoA pilot study suggests the ketogenic diet may ease symptoms of schizophrenia and bipolar disorder...
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
FOX 59 Indianapolis· 3 days agoActinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major ...
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data...
FierceBiotech· 2 days agoNeurocrine Biosciences has nabbed a phase 2 win, with its investigational med in-licensed from...